AU2018368790A1 - Kinase inhibitor compounds and compositions and methods of use - Google Patents

Kinase inhibitor compounds and compositions and methods of use Download PDF

Info

Publication number
AU2018368790A1
AU2018368790A1 AU2018368790A AU2018368790A AU2018368790A1 AU 2018368790 A1 AU2018368790 A1 AU 2018368790A1 AU 2018368790 A AU2018368790 A AU 2018368790A AU 2018368790 A AU2018368790 A AU 2018368790A AU 2018368790 A1 AU2018368790 A1 AU 2018368790A1
Authority
AU
Australia
Prior art keywords
compound
subject
diabetes
cell
esi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2018368790A
Other languages
English (en)
Inventor
Robert Devita
Kunal KUMAR
Hailing Li
Peter MAN-UN UNG
Avner SCHLESSINGER
Andrew Stewart
Hui Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icahn School of Medicine at Mount Sinai
Original Assignee
Icahn School of Medicine at Mount Sinai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icahn School of Medicine at Mount Sinai filed Critical Icahn School of Medicine at Mount Sinai
Publication of AU2018368790A1 publication Critical patent/AU2018368790A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2018368790A 2017-11-20 2018-11-20 Kinase inhibitor compounds and compositions and methods of use Abandoned AU2018368790A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762588792P 2017-11-20 2017-11-20
US62/588,792 2017-11-20
PCT/US2018/062023 WO2019100062A1 (en) 2017-11-20 2018-11-20 Kinase inhibitor compounds and compositions and methods of use

Publications (1)

Publication Number Publication Date
AU2018368790A1 true AU2018368790A1 (en) 2020-06-25

Family

ID=66539149

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018368790A Abandoned AU2018368790A1 (en) 2017-11-20 2018-11-20 Kinase inhibitor compounds and compositions and methods of use

Country Status (7)

Country Link
US (1) US11547712B2 (cg-RX-API-DMAC10.html)
EP (1) EP3717475B1 (cg-RX-API-DMAC10.html)
JP (1) JP2021503486A (cg-RX-API-DMAC10.html)
CN (1) CN111936490A (cg-RX-API-DMAC10.html)
AU (1) AU2018368790A1 (cg-RX-API-DMAC10.html)
CA (1) CA3084581A1 (cg-RX-API-DMAC10.html)
WO (1) WO2019100062A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021510153A (ja) 2018-01-05 2021-04-15 アイカーン スクール オブ メディシン アット マウント サイナイ 膵臓ベータ細胞の増殖を増加させる方法、治療方法、および組成物
ES3038913T3 (en) 2018-03-20 2025-10-15 Icahn School Med Mount Sinai Beta-carboline derivatives as dyrk1a inhibitors for the treatment of e.g. diabetes
WO2025231425A1 (en) * 2024-05-03 2025-11-06 Biosplice Therapeutics, Inc. 4-aminopyrrolo[2,l-f][l,2,4]triazines and preparation and uses thereof

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200301123A (en) 2001-12-21 2003-07-01 Astrazeneca Uk Ltd New use
WO2004026306A2 (en) 2002-09-18 2004-04-01 Pfizer Products Inc. Pyrazole derivatives as transforming growth factor (tgf) inhibitors
JP4896518B2 (ja) 2002-12-13 2012-03-14 ワイエム・バイオサイエンシズ・オーストラリア・ピーティーワイ・リミテッド ニコチンアミド系キナーゼ阻害薬
AU2003297460A1 (en) 2002-12-19 2004-07-14 Scios, Inc. TREATMENT OF OBESITY AND ASSOCIATED CONDITIONS WITH TGF-Beta INHIBITORS
US20050032869A1 (en) 2003-07-08 2005-02-10 Pharmacia Italia S.P.A. Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
US20090196912A1 (en) 2004-07-30 2009-08-06 Gpc Botech Ag Pyridinylamines
DK1789044T3 (da) 2004-09-06 2010-12-06 Basilea Pharmaceutica Ag Phenylaminopyridiner og phenylaminopyraziner
WO2007084667A2 (en) 2006-01-19 2007-07-26 Osi Pharmaceutical, Inc. Fused heterobicyclic kinase inhibitors
BRPI0807961A2 (pt) 2007-02-13 2017-05-16 Pharmacopeia Llc agonista de alfa2c adrenorreceptor funcionalmente seletivos.
GB0705566D0 (en) 2007-03-23 2007-05-02 Univ Dundee Method of treating learning impairment in down's syndrome subjects
EP2178537A4 (en) 2007-07-19 2011-08-17 Merck Sharp & Dohme BETA-CARBOLIN DERIVATIVES AS ANTIDIBLE COMPOUNDS
EP2265603B1 (en) 2008-03-13 2014-05-07 The General Hospital Corporation Inhibitors of the bmp signaling pathway
US20100173931A1 (en) 2009-01-06 2010-07-08 Osteogenex Inc. Harmine derivatives for reducing body weight
WO2010123583A2 (en) 2009-04-24 2010-10-28 University Of Tennessee Research Foundation 1-aryl or 1-heteroaryl-pyrido[b]indoles and uses thereof
AU2010247412A1 (en) 2009-05-15 2011-11-24 Novartis Ag 5-pyridin-3-yl-1,3-dihydro-indol-2-on derivatives and their use as modulators of aldosterone synthase and/or CYP11B1
WO2010135589A2 (en) 2009-05-20 2010-11-25 Sakura Properties, Llc Dietary supplement drink for delivery of resveratrol and other polyphenols
JP2011006408A (ja) * 2009-05-29 2011-01-13 Sumitomo Chemical Co Ltd 神経栄養因子の活性が関与する疾患の治療または予防剤
CN102791134B (zh) 2009-12-04 2015-04-22 魄金莱默有限公司 用多巴胺再摄取抑制剂及类似物治疗糖尿病症状和延迟或预防糖尿病相关病理学病况的方法
WO2011075665A2 (en) 2009-12-18 2011-06-23 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
US20130102627A1 (en) 2010-04-09 2013-04-25 The Brigham And Women's Hospital, Inc. Acridines As Inhibitors Of Haspin And DYRK Kinases
WO2011133795A2 (en) 2010-04-22 2011-10-27 The Brigham And Women's Hospital, Inc. Beta-carbolines as inhibitors of haspin and dyrk kinases
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
MX341025B (es) 2010-05-05 2016-08-04 Boehringer Ingelheim Int Gmbh * Terapia de combinacion.
US9168247B2 (en) 2010-06-25 2015-10-27 Facultes Universitaires Notre Dame De La Paix Beta carboline derivatives useful in the treatment of proliferative disorders
AU2011290123B2 (en) 2010-08-09 2016-11-10 Takeda Pharmaceutical Company Limited Method of producing pancreatic hormone-producing cells
US20130165474A1 (en) 2010-08-17 2013-06-27 Travis Dunckley Compounds that inhibit tau phosphorylation
KR102006749B1 (ko) 2011-08-19 2019-08-02 디악쏘니 Dyrk1 억제제 및 이의 용도
CN103070862A (zh) 2011-10-25 2013-05-01 新疆华世丹药物研究有限责任公司 去氢骆驼蓬碱衍生物在制备抗菌药物中的应用
WO2013119518A1 (en) 2012-02-06 2013-08-15 The Regents Of The University Of California Small molecules for islet expansion
AU2013284460A1 (en) 2012-06-27 2015-01-29 Dmnomore CTLA4 fusion proteins for the treatment of diabetes
CN105142621A (zh) 2012-10-24 2015-12-09 国家健康科学研究所 用于预防或治疗糖尿病和促进β-细胞存活的TPL2激酶抑制剂
JP2016500080A (ja) 2012-11-26 2016-01-07 新疆華世丹薬物研究有限責任公司 ビスβ−カルボリン系化合物、その製造方法、医薬組成物および用途
JPWO2014058080A1 (ja) 2012-11-30 2016-09-05 国立研究開発法人理化学研究所 体細胞のリプログラミングを亢進させる方法、及び細胞作製キット
CN102977096B (zh) 2012-12-07 2014-12-17 中国药科大学 具有靶向特性的去氢骆驼蓬碱衍生物的抗肿瘤前药
MX2015007097A (es) 2012-12-10 2015-09-29 Hoffmann La Roche Nuevas fenil-piridinas/pirazinas bi-anulares para el tratamiento de cancer.
US20150174034A1 (en) * 2013-03-13 2015-06-25 Avon Products, Inc. Tyrosinase inhibitors
SI2968284T1 (sl) 2013-03-14 2021-08-31 Osteoqc Inc. Alkil-amin harmin derivati za pospeševanje rasti kosti
WO2014151682A1 (en) 2013-03-14 2014-09-25 Icahn School Of Medicine At Mount Sinai Pyrimidine compounds as kinase inhibitors
CN105555785B (zh) * 2013-06-18 2019-03-01 4Sc股份公司 作为dyrk激酶抑制剂的2,3-二氢苯并呋喃-5-基化合物
GB2519623A (en) 2013-06-18 2015-04-29 4Sc Discovery Gmbh Method of inhibiting DYRK1B
US9725463B2 (en) 2013-06-21 2017-08-08 Lupin Limited Substituted heterocyclic compounds as CRAC modulators
ES2529865B8 (es) 2013-07-25 2016-01-22 Fundación Para La Investigación Biomédica Del Hospital Universitario La Paz (Fibhulp) USO DE COMPUESTOS DERIVADOS DE SALES DE PIRIDAZINO[1',6':1,2]PIRIDO[3,4-b]INDOLINIO COMO AGENTES ANTIINFLAMATORIOS
SI3057959T1 (en) 2013-10-17 2018-07-31 Vertex Pharmaceuticals Incorporated DNA-PK INHIBITORS
JP6767875B2 (ja) 2014-04-08 2020-10-14 ライジェル ファーマシューティカルズ, インコーポレイテッド Tgf−ベータ阻害剤としての2,3−二置換ピリジン化合物および使用方法
US20170280720A1 (en) 2014-09-17 2017-10-05 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
ES2985135T3 (es) 2014-12-18 2024-11-04 Harvard College Procedimientos para generar células ß derivadas de células madre y usos de las mismas
ES2820768T3 (es) 2015-04-03 2021-04-22 Xoma Technology Ltd Tratamiento del cáncer usando inhibidores de TGF-beta y PD-1
US11332716B2 (en) 2015-07-27 2022-05-17 The Regents Of The University Of California Methods and compositions for producing pancreatic beta cells
AU2016315881B2 (en) 2015-09-03 2019-09-19 The Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of DYRK1A and uses thereof
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
CN105884767B (zh) 2015-11-24 2018-01-19 西华大学 9‑位取代的吡啶并[3,4‑b]吲哚衍生物及其制备方法和作为SIRT蛋白抑制剂的用途
EP3389720A1 (en) 2015-12-18 2018-10-24 The General Hospital Corporation Polyacetal polymers, conjugates, particles and uses thereof
US10487087B2 (en) 2015-12-30 2019-11-26 Vanderbilt University Positive allosteric modulators of the GLP-1 receptor
WO2017168245A1 (en) 2016-04-01 2017-10-05 University Of Limerick Pharmaceutical compositions and methods for the treatment of diabetes
WO2017197151A1 (en) 2016-05-11 2017-11-16 Emory University Phosphotidylinositol 3-kinase inhibitors
WO2018081401A1 (en) 2016-10-26 2018-05-03 Ichan School Of Medicine At Mount Sinai Method for increasing cell proliferation in pancreatic beta cells, treatmen t method.and composition
EP3318563A1 (en) 2016-11-07 2018-05-09 Sanofi Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders
US11279703B2 (en) 2016-12-01 2022-03-22 Aptose Biosciences Inc. Fused pyrimidine compounds as BRD4 and JAK2 dual inhibitors and methods for use thereof
JP2021510153A (ja) 2018-01-05 2021-04-15 アイカーン スクール オブ メディシン アット マウント サイナイ 膵臓ベータ細胞の増殖を増加させる方法、治療方法、および組成物
ES3038913T3 (en) 2018-03-20 2025-10-15 Icahn School Med Mount Sinai Beta-carboline derivatives as dyrk1a inhibitors for the treatment of e.g. diabetes
CA3124700A1 (en) 2018-12-31 2020-07-09 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
CA3124353A1 (en) 2018-12-31 2020-07-09 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use

Also Published As

Publication number Publication date
JP2021503486A (ja) 2021-02-12
EP3717475B1 (en) 2023-06-07
WO2019100062A1 (en) 2019-05-23
US20200306257A1 (en) 2020-10-01
EP3717475A1 (en) 2020-10-07
CN111936490A (zh) 2020-11-13
US11547712B2 (en) 2023-01-10
CA3084581A1 (en) 2019-05-23
EP3717475A4 (en) 2021-03-24

Similar Documents

Publication Publication Date Title
US12421232B2 (en) Kinase inhibitor compounds and compositions and methods of use
KR102011770B1 (ko) 치환된 피리도피리미딘 화합물 및 flt3 억제제로서의 이의 용도
US20230234935A1 (en) Kinase inhibitor compounds and compositions and methods of use
US20220064146A1 (en) Kinase inhibitor compounds and compositions and methods of use
WO2012068546A1 (en) Heterocycle amines and uses thereof
EP3906233B1 (en) Kinase inhibitor compounds and compositions and methods of use
US10744128B2 (en) 6-(5-membered heteroaryl)isoquinolin-3-yl-(5-membered heteroaryl) carboxamides and preparation and use thereof
WO2009070583A1 (en) Pyrido[3,2-e]pyrazines, process for preparing the same, and their use as inhibitors of phosphodiesterase 10
EP3717475B1 (en) Kinase inhibitor compounds and compositions and methods of use
WO2002076396A2 (en) Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
HK40063467A (en) Kinase inhibitor compounds and compositions and methods of use
HK40062251A (en) Kinase inhibitor compounds and compositions and methods of use

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period